Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist. With IC50s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects[1][2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,080.00 | |
50 mg | 10-14 weeks | $ 1,410.00 | |
100 mg | 10-14 weeks | $ 2,250.00 |
Description | BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist. With IC50s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects[1][2]. |
Targets&IC50 | PAR4 (human):9.5 nM, PAR4 (monkey):2.1 nM |
In vitro | BMS-986120 has high binding affinity to PAR4 expressed on HEK293 cells. And it inhibition of PAR4-induced calcium mobilization with an IC50 of 0.56 nM[3]. |
In vivo | BMS, administered at dosages of 0.2, 0.5, and 1 mg/kg, decreases tail withdrawal (TW) by 35±5, 49±4, and 83±4%, respectively. In monkeys, a 1 mg/kg dose of BMS shows no inhibition of platelet aggregation (PA) triggered by PAR1-AP, ADP, and collagen, indicating selectivity. The maximum increases observed in kaolin bleeding time (KBT) and mepacrine bleeding time (MBT) are limited to 2.2-fold and 1.8-fold, respectively[1]. |
Molecular Weight | 513.59 |
Formula | C23H23N5O5S2 |
CAS No. | 1478712-37-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-986120 1478712-37-6 Others BMS986120 BMS 986120 inhibitor inhibit